Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates,omega-3 fatty acid compounds, and PCSK9…
Metformin is the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. The emergence of more-effective…
Renal anemia is a common complication of chronic kidney disease (CKD). The primary goal of treatment of renal anemia is to increase and maintain Hb levels and reduce the risk of complications of…
The treatment journey for multiple sclerosis (MS) patients in the United States continues to evolve; nearly 20 immunomodulatory disease-modifying therapies (DMTs) are now available to treat the…
First-line treatment of chronic heart failure (CHF) usually involves an angiotensin-converting enzyme (ACE) inhibitor, an oral beta blocker, or an oral diuretic. The addition of a second- or third-…
Although heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all chronic heart failure cases and understanding of the disease’s pathophysiology has improved…
Drug treatment of chronic heart failure with reduced ejection fraction (HFrEF) is well established, with a wealth of supporting evidence from clinical trials. ACE inhibitors or ARBs, beta blockers…
More than 30 million people in the United States are afflicted with osteoarthritic (OA) pain; we expect an aging population and the increasing prevalence of obesity to drive further growth…
Characterized by an abnormal heart rhythm that starts in the atrial chambers, atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Management of AF targets the prevention…
Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…
Painful diabetic neuropathy (PDN) afflicts more than three million people in the United States. It characterized by numbness, tingling, and burning, sharp, shooting or other painful sensations,…